A guide to blood component and protein plasma product administration Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 1 Nova Scotia Provincial Blood Coordinating Team Room 107 –MacKenzie Building 5788 University Avenue Halifax, NS B3H 1V8 Phone: (902) 487-0514 Fax: (902) 422- 0893 Email: [email protected] Website: http://www.cdha.nshealth.ca/nova-scotia-provincial-blood-coordinating-team The production of this Guide to Blood Component and Protein Plasma Product Administration has been made possible through a financial contribution from the Public Health Agency of Canada. Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 2 Definitions ABO & Rh ‘Type’ General Transfusion Testing patients’ red cells and plasma/serum to identify Practices ABO blood type and Rh (D) blood type. Antibody Screen ‘Screen’ COMPATIBILITY TESTING Testing the patients’ plasma/serum for allo-and/or auto-antibodies usually Crossmatching must be performed for all red cell developed after transfusion or following pregnancy. components. Type and screen should be ordered if transfusion is Antibody Investigation possible but unlikely. Crossmatch should be ordered Extensive testing of the patients’ plasma/serum to identify new and/or if transfusion is likely. reconfirm previously identified clinically significant antibodies. STORAGE TEMPERATURE Blood Components Blood components and blood products are stored A therapeutic component of blood intended for transfusion (e.g. red cells, according to facility temperature and storage device granulocytes, platelets, plasma) that can be prepared using the equipment policies. In order for blood components or blood and techniques available in a blood center. products to be re-issued from BTS, unused products Blood Products (Plasma Protein Products) must be returned to BTS within 30 minutes of Therapeutic products produced with a manufacturing process that pools dispensing and BTS will determine whether the plasma from many donors. blood components/blood products can be safely returned to inventory or discarded. BTS- Blood Transfusion Service – Blood bank. CAUTION: Do not store blood in an unmonitored refrigerator. DAT-Direct Antiglobulin Test Testing of patient red cells to determine if they are coated with antibody or PRE -TRANSFUSION complement. Used in the investigation of adverse transfusion events, Verify prescriber’s order. autoimmune hemolytic anemia, drug induced hemolysis, hemolytic disease of the fetus and newborn. Verify that consent was obtained. Provide transfusion pamphlet information Group & Screen/Type & Screen for patient. Testing performed on a patient’s blood sample which includes ABO & Rh Verify patient and blood unit identification. and antibody screen. Verify special product requirements. Serological/Electronic Crossmatch Testing, manually or electronically, of the patient’s plasma/serum with donor red cells to determine compatibility. Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 3 DOCUMENTATION AND MONITORING COMPATIBLE INTRAVENOUS SOLUTIONS 1. Document vital sign intervals within Components: Use 0.9% NaCl solutions 1 hour prior to administration, minimum DO NOT use Dextrose solutions as they may induce of 15 minutes after starting, hourly until hemolysis transfusion completed and 20-60 minutes following completion of transfusion DO NOT use Lactated Ringer’s as it may induce clot 2. Complete bedside verification prior to starting transfusion. formation in the blood bag and/or tubing. 3. Monitor patient during and after transfusion for signs of an adverse transfusion reaction. Products: Follow manufacturer’s instructions for 4. Document volume administered and transfusion specific products and fluid compatibility reaction. 5. Complete patient notification process. TIME OF INFUSION For more details on this process, consult the Blood Component and Blood Blood components or blood products must be Product Administration policy CL-BP-030 infused within 4 hours of removal from a temperature controlled storage area. FILTERS Before ordering blood components from BTS Filter all blood components through a standard ensure your patient is ready for transfusion: (i.e. consent obtained, IV patent, etc.) (170-260 micron) blood filter. Refer to transplantation or nursing protocol for If there is an unexpected delay in starting the infusion of HPCs (stem cells). transfusion, return unused blood components or blood products immediately to BTS so lab Blood products may require special infusion sets, personnel may determine if it can be safely consult monograph. returned to inventory or discarded. MEDICATION WARMING CAUTION! Medication must not be added to or If warming is needed, a calibrated piggy-backed with any blood component or blood warming device must be used to plasma derivative. ensure the blood is not warmed to a temperature at which red cell PUMPS hemolysis occurs (do not exceed 42◦C). Use of infusion pumps is component/ product A prescriber’s order is required. specific. Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 4 Red Blood Cells (RBC) STORAGE TEMPERATURE Red cells are stored in a controlled ABO/Rh COMPATIBILITY BTS refrigerator between 1- 6ºC. Red cell ABO group and Rh specific components are preferred (1st Option); however ABO group FILTERS and Rh compatible red cells are acceptable ALL red cell components must be administered (2nd Option). through a standard (170-260 micron) blood filter. TIME OF INFUSION Red cells must complete infusion within 4 hours of removal from a temperature Patient ABO Group Donor ABO 1st Donor ABO 2nd Choice controlled storage area. Choice A A O MEDICATION B B O DO NOT add, piggyback or push medication AB AB A, B, O with red cell components. O O ------------ Unknown O ------------ COMPATIBLE INTRAVENOUS SOLUTIONS 0.9% NaCl injection. Patient Rh Donor Rh 1st Choice Donor Rh 2nd Choice Positive Positive Negative PUMPS Positive Acceptable for use. Negative Negative (All males and women 45 years or older. Consider use of anti-D Ig for women under 45) SPIKING TECHNIQUE Do not over- spike the blood units: over-spiking will result in inability to remove the infusion set. Always insert/remove the infusion set using one quarter turn motions. Insert with one quarter turn, clockwise twists and remove with one quarter turn, counter clockwise twists. Do not twist in both directions while spiking or un-spiking. Pulling the spike out in a straight downward motion will result in the tightening of the port on the spike. Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 5 Platelet ABO Selection Chart Platelets Patient ABO Group Donor ABO Specific Donor non-ABO ABO COMPATIBILITY 1st choice Specific 2nd choice For platelets, ABO specific transfusion is preferable but A A AB* not required. The donor plasma in platelet components should be ABO compatible with the recipient’s red B B AB* cells when possible. In cases where ABO specific platelets (1st Option) are not available, see the Platelet AB AB BTS to consult Medical ABO Selection Chart for donor non-specific 2nd choice. Director O O A, B, AB Unknown AB BTS to consult Medical Director nd *If specific 2 choice is unavailable, a different ABO group may be used OFwith INFUSION Medical Director approval. COMPATIBILITY TESTING TIME OF INFUSION ABO/Rh identification of recipient required. Should administer as rapidly as patient can tolerate (20 min. adult average). STORAGE TEMPERATURE Must complete infusion within four hours of 20-24°C (room temperature). dispensing from a temperature controlled storage area. DO NOT REFRIGERATE PLATELETS. MEDICATION FILTERS DO NOT add piggyback or push medication with ALL platelets must be administered through platelet concentrates. a standard (170-260 micron) blood filter. PUMPS . Rh COMPATIBILITY Platelets may be infused via a Fresenius Kabi pump Rh -negative platelet concentrates can be given to Rh-positive patients. If Rh-positive platelet concentrates are given to Rh- negative patients, the use of Rh Immune Globulin (RhIg) should be given to women of child-bearing age and considered for women (greater than 45 years of age), and men. Blood Transfusion Therapy: A Guide to Blood Component and Blood Product Administration, 2019 6 Plasma and COMPATIBILITY TESTING ABO identification of recipient required. Cryoprecipitate STORAGE TEMPERATURE Plasma and cryoprecipitate are stored frozen TYPES OF COMPONENTS and require 30 - 60 minutes to prepare for use. Type Volume/Unit Multiple units of cryoprecipitate may be pooled together (at specific BTS sites). Plasma (AFFP/FP) AFFP ~494mL FP ~ 283mL Cryosupernatant Plasma ~273mL FILTERS Plasma and cryoprecipitate must be administered Cryoprecipitate (CRYO) ~10mL (Some sites may pool through a blood filter (170-260 micron). CRYO into ~100mL bags) TIME OF INFUSION ABO COMPATIBILITY Must complete infusion within four hours of dispense from a temperature controlled Plasma components must be ABO compatible. storage area. Transfuse as rapidly as Cryoprecipitate does not require ABO compatibility for clinically tolerated and as specified by adult transfusions, but is preferred for pediatrics. authorized prescriber. Patient ABO Donor Group Donor Group MEDICATION Group 1st Choice 2nd Choice DO NOT add, push or piggyback medication with plasma or cryoprecipitate. A A AB B B AB PUMPS Acceptable for use. AB AB ---------- O O A, B, AB Unknown AB ---------- Rh - Plasma